The Directory of Pharma Companies and News

Addex Therapeutics

Addex Therapeutics logo
Addex Therapeutics ( is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase IIA POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase IIB for PD-LID. In parallel, dipraglurant’s therapeutic use in dystonia and treatment resistant depression is being investigated. Addex second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc. Addex also has several preclinical programs including: ADX71441 (GABAB receptor PAM) which has received regulatory approval to start Phase I and is being investigated for therapeutic use in Charcot-Marie-Tooth (Type 1A) disease, alcohol use disorder and nicotine dependence; mGluR4PAM for drug abuse and dependence, Parkinson’s disease and other neurodegenerative diseases; mGluR2NAM for treatment resistant depression and cognitive deficits; mGluR7NAM for psychosomatic disorders, TrkBPAM for neurodegenerative disorders; and GLP1PAM for type 2 diabetes. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention – the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.
Category: Biotech
Category: Biotech

Addex Therapeutics News

2017-02-28Addex Raises CHF3.0 million Through Private Placement of Treasury Shares and Extends Cash Runway Through 2018
2017-02-27Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
2017-02-06Addex’s Clinical Programs and Discovery Platform Highlighted in Review of Allosteric Modulators for the Treatment of N...
2017-01-31Addex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson’s Dise...
2017-01-09Addex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Os...
2016-07-27Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity.
2016-07-20LifeSci Capital Issues Equity Research Report on Addex Therapeutics
2016-06-24Addex Shareholders Approved all Board Proposals at 2016 Annual General Meeting
2016-06-13Addex mGluR4 and mGluR7 Programs Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseas...
2016-06-09Addex ADX71441 Demonstrates Positive Results in Non-Human Primate Model of Cocaine Addiction
2016-06-08Van Leeuwenhoeck Issues Research Note on Addex Therapeutics
2016-06-02Addex Annual General Meeting Scheduled for 23 June 2016
2016-06-02Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder S...
2016-05-30Addex Increases Issued Share Capital and Creates Treasury Shares
2016-04-29Addex Therapeutics Reports 2015 Financial Results
2016-04-11Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
2016-03-15Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers
2016-01-11Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data ...
2016-01-04Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Park...
2015-12-17Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occup...
2015-12-15Addex and University of Geneva Collaborators Awarded Swiss Grant to Profile Addex TrkB Allosteric Modulators as Neuropro...
2015-12-09Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple ...
2015-12-07Addex Moves R&D Operations to Geneva’s Campus Biotech
2015-11-25Addex ADX71441 Included in the NINDS Anticonvulsant Screening Program
2015-11-23Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR7 and mGluR4 Allosteric Modulators for Neuro...
2015-11-19ValuationLAB Issues Research Report on Addex Therapeutics with Share Price Estimate of CHF5.2 per Share
2015-10-13Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder
2015-09-30Addex Therapeutics Reports First Half 2015 Financial Results
2015-09-23Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
2015-09-07Pierre Fabre Pharmaceuticals and Addex Therapeutics Sign Early-Stage Agreement in the Central Nervous System (CNS) Field
2015-08-17Alpha Deal Group Initiates Independent Research Coverage on Addex Therapeutics
2015-08-14Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for...
2015-08-05valuationLAB Issues Research Report on Addex Therapeutics
2015-07-22Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and...
2015-06-12Addex Shareholders Appoint Raymond Hill and Tim Dyer to the Board of Directors and approve all Board Proposals at Annual...
2015-06-03Addex Identifies New Potential Use of mGlu7 receptor NAMs to Treat Stress-Induced Visceral Pain
2015-05-29Addex and Prof. Pisani Present Dipraglurant data in Rare Inherited Forms of Dystonia
2015-05-27Addex Annual General Meeting Scheduled for 11 June 2015
2015-05-06Addex Enters Collaboration with Prof. Pisani to Explore the Therapeutic use of Dipraglurant in the Treatment of Rare Inh...
2015-04-30Addex Therapeutics Reports 2014 Financial Results
2015-03-09Addex Raises CHF2.8 million in a Private Placement and Extends Cash Runway Through 2017
2015-02-23Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Fundi...
2015-02-19Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death
2015-01-19Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in th...
2015-01-09Addex Completes 2014 with Strong Cash Position and Provides 2015 Strategic Update
2015-01-07Addex and NIAAA Enter Collaboration to Evaluate ADX71441 in Alcohol Use Disorder
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.